The FDA has approved several generic versions of pregabalin for the treatment of patients with neuropathic pain related to diabetic neuropathy, postherpetic neuralgia, partial onset seizures, fibromyalgia and spinal cord injury.

“Today’s approval of the first generics for pregabalin, a widely-used medication, is another example of the FDA’s longstanding commitment to advance patient access to lower cost, high-quality generic medicines,” Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research, said in a press release. “The FDA requires that generic drugs meet rigorous scientific and quality standards. Efficiently bringing safe and effective generics to market so patients have more options to treat their conditions is a top priority for the FDA.”